Sponsors

Early diagnosis of RA

  •  

The Binding SiteÆs new, highly specific and sensitive secondgeneration anti-CCP2 enzyme-linked immunosorbent assay (ELISA) kit is the latest addition to the companyÆs comprehensive range of autoimmune BINDAZYME assays.

The kit is intended as an aid in the early diagnosis of rheumatoid arthritis, measuring specific IgG autoantibodies against secondgeneration cyclic citrullinated peptides (CCP2) in human serum.

In common with all BINDAZYME assays, the new anti-CCP2 kit is automation friendly and easy to use. Its single-well ‘break apart’ format makes it cost effective and suitable for various levels of workload.

www.bindingsite.co.uk

Other News

Leeds Hosts NPIC Summit 2026

News

Jun 11, 2026
Positive results for Lassa fever vaccine in phase 1 clinical trial

News

Jun 09, 2026
Genomics England Chair to step down

News

Jun 09, 2026
New antibiotic design could help treat drug-resistant infections

News

Jun 09, 2026
Joint venture aims to advance precision oncology

News

Jun 09, 2026
Tethis launches SmartBioSurface slides

News

Jun 08, 2026
NHS diagnostic waiting list could exceed two million people in 2027

News

Jun 08, 2026
Thermo Fisher Scientific expands mass spectrometry offering

News

Jun 08, 2026
Roche rapidly develops a PCR test for Ebola

News

Jun 05, 2026

Latest Issues

Nova Biomedical

Nova Biomedical develops, manufactures, and sells advanced technology blood testing analyzers. We employ over 1,000 people, with sales and service subsidiaries in eight countries and distributors in more than 90 additional countries. Nova has manufacturing facilities in Waltham and Billerica, Massachusetts, Belo Horizonte, Brazil and in Taipei,...

Learn more »

Weqas Annual Laboratory Conference 2026

St Andrew’s Stadium, Birmingham
11th June 2026

European Human Genetics Conference

Svenska Mässan, Gothenburg, Sweden
13-16 June, 2026

24th European Pathology Congress

Paris, France
22-23 June, 2026

Manchester Pathology 2026

Manchester
23-25 June, 2026